Amphastar Pharma (AMPH) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
March 24, 2015 4:01 PM EDTRANCHO CUCAMONGA, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) ("Amphastar" or the "Company") today reported results for the fourth quarter ended December 31, 2014.
Net revenues of $55.9 million for the fourth quarter GAAP net loss of $2.5 million, or $0.06 per diluted share for the fourth quarter Adjusted non-GAAP net loss of $1.5 million, or $0.03 per diluted share for the fourth quarter  Three Months Ended December 31, Years Ended December 31,  2014 2013 2014 2013  (in thousands, except per share data) Net revenues... More